Boundless Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $51.86M
- P/E (TTM)
- –
- Dividend yield
- –
About Boundless Bio
Pharmaceutical Preparations, SIC 2834
Boundless Bio is a clinical-stage oncology company developing extrachromosomal DNA directed therapeutics to treat oncogene amplified cancers. Using its proprietary Spyglass platform, the company identifies synthetic lethal targets essential for extrachromosomal DNA function and designs small molecule therapies to inhibit them. Its lead product candidate, BBI-940, is an oral selective degrader targeting a kinesin involved in DNA segregation during mitosis, which entered a Phase 1 clinical trial for patients with certain types of breast cancer.
The company operates in the United States and manages its primary business and clinical research activities from California. Its corporate headquarters and principal executive offices are located in San Diego, California.
Summary of the business section of Boundless Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Boundless Bio, Inc.
- Founded
- 2018
- Headquarters
- La Jolla, CA
- Address
- 11099 North Torrey Pines Road, Suite 150 92037
- Phone
- (858) 766-9912
- Website
- boundlessbio.com
- Employees
- 28, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Diego, CA
Stock & identifiers
- Ticker
- BOLD
- Exchange
- Nasdaq
- IPO date
- Mar 28, 2024
- Shares outstanding
- 23M, Aug 5, 2026
- Public float
- $18.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1782303
- CUSIP
- 10170A100
- ISIN
- US10170A1007
- EIN
- 83-0751369
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Zachary Hornby | President & CEO, Director | 256,410 |
| Jessica Oien | See Remarks | – |
| Robert Doebele | Chief Medical Officer | – |
| David A. Hinkle | See Remarks | 100 |
| Christian Hassig | Chief Scientific Officer | 25,641 |
| Jennifer Lew | Director | – |
| Jonathan E. Lim | Director | 653,479 |
| James Christensen | Director | – |
| Nancy Whiting | Director | – |
| Christine Brennan | Director | – |
Employees
Headcount reported in annual reports
“As of March 8, 2026, we had 28 employees, all of whom are full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 8, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Mar 28, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 22, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |